Cargando…
1146. Real-World Experience Highlighting Tocilizumab Use in the Treatment of COVID-19
BACKGROUND: Tocilizumab (TCZ) was approved by the Food and Drug Administration under emergency use authorization for treatment of COVID-19 in patients requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation. Despite multiple clinical tri...
Autores principales: | Maguire, Christina, Terico, Adrienne, Patel, Hinal, Anesi, George L, Degnan, Kathleen, Dutcher, Lauren, Hamilton, Keith W, Meyer, Nuala J, Talati, Naasha J, Saw, Steve |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752726/ http://dx.doi.org/10.1093/ofid/ofac492.984 |
Ejemplares similares
-
The Penn Medicine COVID-19 Therapeutics Committee—Reflections on a Model for Rapid Evidence Review and Dynamic Practice Recommendations During a Public Health Emergency
por: Anesi, George L, et al.
Publicado: (2023) -
82. Assessment of Clinical Outcomes and Antibiotic Prescribing Patterns Following Implementation of the GenMark ePlex(®) Blood Culture Identification Panel for Gram-positive Bloodstream Infections
por: Wein, Megan, et al.
Publicado: (2021) -
Cavity for 114.6 MHz
por: Croizat, M, et al.
Publicado: (1984) -
1759. Risk Factors for OPAT-Related Adverse Drug Events: A Case-Control Study
por: Burke, Elysia, et al.
Publicado: (2022) -
905. Impact of a Real-Time Electronic Alert on Antibiotic Treatment Duration for Pneumonia in Hospitalized Patients
por: Degnan, Kathleen, et al.
Publicado: (2022)